^
Association details:
| Biomarker: | EGFR exon 19 deletion + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
29P - Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors.
Published date:
03/23/2023
Excerpt:
EGFR mutation types included 13 deletion in exon19, 19 L858R, and 4 uncommon types….The combination treatment of atezolizumab, bevacizumab, pemetrexed, and cisplatin/carboplatin provided favorable efficacy in EGFR mutation-positive NSCLC after TKI failure, and higher PD-L1 expression (≧ 1%) was associated with longer PFS.
Secondary therapy:
cisplatin + pemetrexed; carboplatin + pemetrexed
